DCM
RXST icon

Defilade Capital Management’s RxSight RXST Stock Holding History

Defilade Capital Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-913,090
Closed -$9.51M – 39
2025
Q4 		$9.51M Buy
+913,090
New +$9.16M 1.29% 26

Other funds holding RXST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Defilade Capital Management's RXST Position: Q1 2026 in Review

Defilade Capital Management sold out of RxSight (RXST) in Q1 2026, closing a stake of 913,090 shares — an estimated $9.51M sold.

Defilade Capital Management first reported a position in RXST in Q4 2025 and held it in 1 quarter. The position peaked at $9.51M in Q4 2025. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • Defilade Capital Management reported no remaining RxSight position as of Q1 2026 after selling out during the quarter.
  • Defilade Capital Management sold 913,090 RxSight shares in Q1 2026, an estimated $9.51M.
  • Defilade Capital Management first reported a position in RxSight in Q4 2025 and held it in 1 quarter.
  • Defilade Capital Management's RxSight position peaked at $9.51M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Defilade Capital Management's 13F filing for Q1 2026, filed 14 May 2026.